Dr Jason Lester is a Consultant Clinical Oncologist based at The Velindre Cancer Centre in Cardiff.

Dr Lester qualified from Guy's Hospital Medical School, London in 1993 and trained in general medicine in the South East of England. He completed his oncological training in 2003, and was appointed as a Consultant Oncologist at Velindre Cancer Centre the same year, where he is currently Deputy Clinical Director and Lead Clinican for lung cancer in the Trust, bringing vast experience and expertise and offering specialist cancer diagnosis and treatment.

He advises patients on all aspects of Non-surgical treatment of lung cancer, mesothelioma and urological cancers (prostate, kidney and bladder cancer); Chemotherapy and targeted therapy for lung and urological cancers; Stereotactic radiotherapy for early lung cancer; Combined modality therapy for locally advanced lung cancer; Brachytherapy for prostate cancer; IMRT / IGRT radiotherapy for prostate cancer; Bladder sparing treatment for bladder cancer. He is responsible for prescribing and supervising the administration of radiotherapy, radioisotope treatment, cytotoxic chemotherapy and hormone therapy. He is also the Clinical Lead for the All Wales Prostate Cancer Brachytherapy service based at Velindre Cancer Centre. 

Dr Lester is a member of Royal College of Physicians, Fellow of the Royal College of Radiologists, Honorary Research Fellow, Cardiff School of Medicine and British Thoracic Oncology Group Committee Member. He also manages The Stepping Stones Appeal, the Wales-based lung cancer research fund.

Dr Jamie Mills is a Consultant Clinical Oncologist based at The Nottingham University Hospitals NHS Trust.

Dr Mills qualified from University of Leicester Medical School in 2000. After finishing basic medical training his specialist Oncology training took place in Leicester, Northampton and Nottingham.

Dr Mills' areas of specialisation include treatment with novel treatments (e.g. Contact Radiotherapy, SIRT) as well as the most up to date drug treatments. He has specialist interests in Colorectal, Anal and all Urological cancers and with colleagues, he has developed, and implemented Image Guided Intensity Modulated Radiotherapy (IG-IMRT) with Volumetric Modulated Arc Therapy (VMAT) for Prostate cancer, as well as using Tomotherapy to treat Rectal cancer. 

As a member of The Nottingham Oncology Group (TNOG) Dr Jamie Mills is part of a team of 7 Oncologists providing a comprehensive range of treatments for people with cancer. This allows a patient to be seen the same day they enquire.

The Nottingham Oncology Group provides a Consultant presence in the Park Cancer centre every day of the week, so an Expert is always available. Based at the Park Cancer Centre Dr Mills  has access to the diagnostic facilities (CT/ MRI scans and Interventional Radiology), Chemotherapy and Radiotherapy that is needed to treat a cancer, all based on one site. A unique offering for patients in the private sector.

Dr Mills speaks two languages English and French.

He is a member of the Nottingham Oncology Group - Experts in Cancer Care; Expert in Prostate cancer; Rectal Cancer; Early Rectal Cancer; Bowel Cancer; Bladder cancer; Anal cancer; Research using novel drugs and treatments; Technical radiotherapy - IMRT and Image Guided IMRT; VMAT; Selective Internal Radiation Therapy (SIRT), Contact X-Ray Brachytherapy and is a member of the Royal College of Physicians RCP - London 2003; Fellow of the Royal College of Radiologists RCR - London 2008

Affiliations / memberships: American Society Of Therapeutic Radiation Oncology; European Society of Therapeutic Radiation Oncology; British Urology Group; GEC ESTRO Brachytherapy group- Rectal/ anal cancer.

Mr Ashu Gandhi is a Consultant Surgeon based at the Nightingale & Genesis Breast Cancer Prevention Centre, a recognised centre of excellence based at the University Hospital of South Manchester.

This is one of the largest Breast Units in the UK and also one of the busiest breast screening units, receiving referrals from across Greater Manchester and the North West. 

Mr Gandhi is Quality Assurance Surgeon for the North West Breast Screening Quality Assurance team which acts to ensure consistent and high standards of care for women undergoing breast screening in the region. He sits on the Audit & Screening Committee for the Association of Breast Surgery. In addition Mr Gandhi is a member of the Breast Cancer Family History service at the Nightingale & Genesis Centre and member of the Medical Board of The Genesis Breast Cancer Prevention Charity. 

Mr Gandhi is also fully trained and accredited in Thyroid and Parathyroid Surgery. He runs a busy Endocrine Surgery practice at University Hospital of South Manchester and is a core member of the Greater Manchester & Cheshire Thyroid Cancer Team. He is Secretary for the British Association of Endocrine & Thyroid Surgeons and has contributed on their behalf to the British Thyroid Association treatment guidelines.

Mr Gandhi is a member of the Association of Breast Surgery and the British Association of Endocrine & Thyroid Surgeons.

Professor Gerard Byrne is a Consultant Oncoplastic and Aesthetic Breast Specialist Surgeon based in Manchester.

He has been an established Specialist in this field for more than 10 years. He is one of the most experienced and respected Breast Surgeons in the North of England preforming breast cancer and breast reconstruction operations, breast augmentations and breast reductions and symptomatic and cosmetic breast procedures. 

Professor Byrne is a clinical academic surgeon working in the field of breast surgery. As a medical educationalist, he held a number of senior administrative and leadership roles including Hospital Dean for Clinical Studies, and most recently Director of the University Hospital of South Manchester Health education Academy.

He has lead the development of this academy from its inception working in partnership with numerous internal and external public and private stakeholders.  The Academy has focused on a social responsibility strategy which has led to the development of strong local, national and international collaborations. He passionately believes in the strength of the team over the individual and is driven by encouraging others to achieve to their maximum ability. In recognition of his contribution to healthcare education, he was awarded a National Teaching Fellowship; recognised as the highest UK award for education within the higher education community. He recently played a substantial part in the creation of the Greater Manchester Health Innovation and Education Cluster.

Professor Byrne is best known as the director and co-founder of the Universities Medical Assessment Partnership (UMAP) - a partner-funded collaboration of 15 medical schools which develops high quality assessment items for medical examinations. 

Dr Elaine Young is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre at Royal Preston Hospital.

Dr Young qualified from the University of Liverpool in 1988 and gained considerable experience in the field of oncology. She went on to a two year Senior House Officer rotation in general medicine in Liverpool and one year as a Medical Registrar in North Wales. Dr Young first worked in oncology with Trevor Powles at the Royal Marsden Hospital and Undertook Registrar training in clinical oncology at the Christie Hospital in Manchester, before joining the Royal Preston Hospital in 2000 as a Consultant Oncologist, specializing in Breast Cancer, Upper GI Cancer, Chemotherapy & Radiotherapy.

Dr Youngs specialises in Clinical Oncology involving the use of chemotherapy, radiotherapy, endocrine and targeted therapies in the treatment of malignant conditions. She enjoys teaching and is currently involved in the development of undergraduates and postgraduates.

She was Awarded the Henry Briggs memorial medal, in 1998 and the Red Rose Hero award, in 2007.

Dr Duncan McLaren is a Consultant Clinical Oncologist based at The Edinburgh Cancer Centre, Western General Hospital, Edinburgh.

Dr McLaren undertook Undergraduate training at St Mary's Hospital Medical School in London and also undertook an intercalated BSc in Clinical Science where he gained First Class Honours. His General Medical training was at Queens University Hospital Nottingham and he had specialist cancer training at Velindre Cancer Hospital Cardiff. He was given a clinical Fellowship specialising in GU oncology at the British Columbia Cancer Agency, Vancouver and was appointed as Consultant Clinical Oncologist and Honorary Clinical Senior Lecturer at the Edinburgh Cancer Centre in 1998. 

Dr McLaren is a specialist in Genito-Urinary Oncology and runs a large practice offering non-surgical treatment with radiotherapy and chemotherapy for Urological Cancer patients. He has a particular interest in Prostate Brachytherapy (seeds). Edinburgh was the first Scottish Centre to offer this treatment in 2001. He can offer dose-escalated radiotherapy with IMRT for prostate cancer and conformal radiotherapy for bladder cancer. Neoadjuvant chemotherapy is routinely used before surgery or radiotherapy for bladder cancer. He provides the Scottish Prostate Brachytherapy Service in conjunction with Glasgow. The Edinburgh brachytherapy team was honoured to win Hospital Doctor Oncology Team of the year in 2005

Dr McLaren is a member of the Royal College of Radiologists (London), Royal College of Physicians, British Urological Group, South East Scotland GU Cander Group (SCAN), UK and Ireland Brachytherapy Users Group and is appointed to the National Cancer Research Network Clinical Trials (NCRN) group for Prostate Cancer and Bladder Cancer

Dr Charlotte Rees is a Consultant Medical Oncologist based at University Hospital Southampton, where she is the lead for chemotherapy.

Charlotte completed specialist training in medical oncology at The Royal Marsden Hospital between 1996 and 2003. She was also actively involved in the recruitment of patients to phase I to III clinical trials throughout her training and while working for the Institute of Cancer Research at Sutton she was involved in the phase I trials unit.

Dr Rees worked as a consultant in medical oncology and was honorary lecturer at St George’s Hospital, Tooting, London, from 2003 to 2005.

Dr Rees sits on the National Specialist Advisory Committee for Medical Oncology. She is the training programme director for medical oncology for the Wessex deanery and has a Medical Research Council scholarship for BSc in pharmacology. 

Dr Rees is a member of network chemotherapy group and a member of network upper gastrointestinal cancers network group.

Dr Ashoke Biswas is a Consultant Clinical Oncologist at the Rosemere Cancer Centre in Preston.

Dr Biswas Specialises in Head and neck, lymphomas and colorectal cancers.

Dr Andrew Hindley is a Consultant Clinical Oncologist based at The Cancer Centre at Royal Preston Hospital.

Dr Hindley qualified at Birmingham University Medical School in 1977, having been on a travelling scholarship to Malaysia. His elective was spent in oncology at the University of Heidelberg. After training in General Medicine he worked at the Christie Hospital in Clinical Pharmacology, learning how to use anti-cancer drugs, safely and effectively, and carried out research into hormone therapy of breast cancer. He then underwent training in radiotherapy and first became a Consultant in New Zealand prior to taking up his current consultant appointment at Royal Preston Hospital in 1997. 

His clinical interests are in breast cancer, lung cancer, gynaecological, central nervous system and skin cancer. He is actively involved in research into new treatments and training medical students and junior doctors.

His publications have covered hormone therapy and breast cancer, radiotherapy for gynaecological cancer and head and neck cancer, and chemotherapy for gynaecological cancer. His clinical interests are in breast cancer, lung cancer, gynaecological, central nervous system and skin cancer.

In addition to his clinical role Dr Hindley is the Network Clinical Lead for Research and is committed to improving cancer treatment and supportive care for patients in clinical trials. His particular research interests include chemotherapy for platinum resistant disease in ovarian cancer, overcoming unwanted effects of radiotherapy and development of new treatments for brain tumours.

Dr Andrew Gaya is a Consultant Clinical Oncologist based at Guy's and St. Thomas' NHS Foundation Trust.

Dr Gaya originally qualified at St George’s Hospital Medical School (University of London) where he was awarded a distinction and several academic prizes. He trained in Clinical Oncology at Imperial College and St Bartholomew’s Hospital and subsequently undertook a Cancer Research UK MD Fellowship at University College London.

Dr Gaya treats solid tumours using chemotherapy, radiotherapy, and biological therapy – His main focus is on colorectal cancer, cancers of the oesophagus, stomach, pancreas, liver, and lung cancer. Dr Gaya’s main research interest is in the area of functional cancer imaging, where he is looking for ways to assess response to treatment much earlier and techniques for assessing blood flow and oxygen levels within cancers.

He is also heavily involved with the implementation of the latest radiotherapy techniques such as IMRT, IGRT and Tomotherapy, combining targeted or anti-vascular drugs with radiotherapy, and stereotactic body radiosurgery. He is one of the first UK doctors to use the CyberKnife stereotactic body radiosurgery unit. He has published widely in peer-reviewed journals, and is currently lead clinical oncologist for audit and clinical governance at Guy’s and St Thomas’ NHS Foundation Trust.